JP Morgan analyst Yuri Fernandes downgrades Grupo Aval Acciones (NYSE:AVAL) from Neutral to Underweight.
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/16/2023 | Neutral → Underweight | JP Morgan | |
| 12/21/2021 | $6.20 | Sector Outperform → Sector Perform | Scotiabank |
| 8/5/2021 | $5.50 | Underweight → Neutral | JP Morgan |
6-K - Grupo Aval Acciones Y Valores S.A. (0001504764) (Filer)
6-K - Grupo Aval Acciones Y Valores S.A. (0001504764) (Filer)
6-K - Grupo Aval Acciones Y Valores S.A. (0001504764) (Filer)
JP Morgan downgraded Grupo Aval from Neutral to Underweight
Scotiabank downgraded Grupo Aval from Sector Outperform to Sector Perform and set a new price target of $6.20
JP Morgan upgraded Grupo Aval from Underweight to Neutral and set a new price target of $5.50
Grupo Aval Acciones y Valores S.A. ("Grupo Aval" or the "Company") (NYSE:AVAL, BVC: Voting Shares: GRUPOAVAL, Non-Voting Shares: PFAVAL))), announces the filing of its Form 20-F for the year ended December 31, 2023, with the Securities and Exchange Commission (the "SEC"). Grupo Aval's Form 20-F can be accessed by visiting either the SEC's website at www.sec.gov or the Investor Relations section of the Company's website at www.grupoaval.com. In addition, shareholders may receive a hard copy of the Company's audited financial statements under IFRS presented in our Form 20-F, or a complete 2023 Form 20-F including audited financial statements under IFRS, free of charge, by requesting a copy
Grupo Aval Acciones y Valores S.A. ("Grupo Aval" or the "Company") (NYSE:AVAL, BVC: Voting Shares: GRUPOAVAL, Non-Voting Shares: PFAVAL))), announces the filing of its Form 20-F for the year ended December 31, 2022, with the Securities and Exchange Commission (the "SEC"). Grupo Aval's Form 20-F can be accessed by visiting either the SEC's website at www.sec.gov or the Investor Relations section of the Company's website at www.grupoaval.com. In addition, shareholders may receive a hard copy of the Company's audited financial statements under IFRS presented in our Form 20-F, or a complete 2022 Form 20-F including audited financial statements under IFRS, free of charge, by requesting a copy
Grupo Aval Acciones y Valores S.A. ("Grupo Aval" or the "Company") (NYSE:AVAL, BVC: Voting Shares: GRUPOAVAL, Non-Voting Shares: PFAVAL))), announces the filing of its Form 20-F for the year ended December 31, 2021, with the Securities and Exchange Commission (the "SEC"). Grupo Aval's Form 20-F can be accessed by visiting either the SEC's website at www.sec.gov or the Investor Relations section of the Company's website at www.grupoaval.com. In addition, shareholders may receive a hard copy of the Company's audited financial statements under IFRS presented in Form 20-F, or a complete 2021 Form 20-F including audited financial statements under IFRS, free of charge, by requesting a copy from
Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is likely to report earnings for its third quarter. • Movano (NASDAQ:MOVE) is projected to report earnings for its third quarter. • Sypris Solutions (NASDAQ:SYPR) is estimated to report earnings for its third quarter. • LM Funding America (NASDAQ:LMFA) is projected to report earnings for its third quarter. • Milestone Scientific (AMEX:MLSS) is estimated to report earnings for its third quarter. • WiSA Technologies (NASDAQ:WISA) is estimated to report quarterly loss at $0.84 per share on revenue of $550 thousand. • AIM ImmunoTech (AMEX:AIM) is estimated to report quarterly loss at $0.11 per share on revenue of
Grupo Aval Acciones (NYSE:AVAL) is set to give its latest quarterly earnings report on Wednesday, 2023-11-15. Here's what investors need to know before the announcement. Analysts estimate that Grupo Aval Acciones will report an earnings per share (EPS) of $0.08. Grupo Aval Acciones bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Here's a look at Grupo Aval Acciones's past performance and the resulting price change: Quarter Q2
Upgrades UBS upgraded the previous rating for Aemetis Inc (NASDAQ:AMTX) from Neutral to Buy. For the second quarter, Aemetis had an EPS of $0.68, compared to year-ago quarter EPS of $0.01. The stock has a 52-week-high of $10.74 and a 52-week-low of $1.16. At the end of the last trading period, Aemetis closed at $6.16. According to Exane BNP Paribas, the prior rating for Revance Therapeutics Inc (NASDAQ:RVNC) was changed from Underperform to Neutral. In the second quarter, Revance Therapeutics showed an EPS of $0.80, compared to $0.88 from the year-ago quarter. The current stock performance of Revance Therapeutics shows a 52-week-high of $37.98 and a 52-week-low of $17.97. Moreover, at the